Myovant Sciences Ltd. financial metrics

Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q4 2022.

Location
London, United Kingdom
Fiscal year end
31 March
Latest financial report
26 Jan 2023

Quick Takeaways

  • Myovant Sciences Ltd. financial facts are built from SEC company filings data.
  • Latest metrics period on this page: Q4 2022.
  • Headline metric: Return On Equity 37%.

What Changed

  • Return On Equity YoY change: <span class="text-red-600">-43%</span>.
  • Most recent SEC facts end date: 20 Jan 2023.

Why This Matters

  • This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
  • Every metric card links to a deeper SEC-backed history page for verification.

Official SEC Source

Based on latest 10-Q/10-K

Facts and ratios are grounded in SEC company facts linked to the latest 10-Q/10-K cycle.

See Original Filing

Latest SEC snapshot (2023-01-20) highlights Return On Equity 37.1%, Return On Assets -36.5%, and Operating Margin -38.7%.

Financial Quality Score

Transparent 0-100 scoring model based on profitability, financial health, and growth factors.

68.5/100

Balanced Confidence high

Return On Equity

37%

Metric score 100.0/100

Return On Assets

-36%

Metric score 0.0/100

Financial Health

Current Ratio
1.57x
Quick Ratio
1.28x
Debt to Equity
-1.92x

Strengths

Return On Equity, Current Ratio, and Quick Ratio

Watchpoints

Return On Assets, Operating Margin, and Debt-to-equity

Key metrics snapshot

Return On Equity

37%

YoY: -43%

Industry median: -43% (n=675)

View history

Return On Assets

-36%

YoY: +10%

Industry median: -47% (n=673)

View history

Operating Margin

-39%

YoY: -64%

Industry median: -121% (n=298)

View history

Current Ratio

1.57x

YoY: -26%

Industry median: 3.39x (n=667)

View history

Quick Ratio

1.28x

YoY: -37%

Industry median: 1.51x (n=289)

View history

Debt-to-equity

-1.92x

YoY: -30%

Industry median: 0.26x (n=530)

View history

Revenues YoY

91%

YoY:

Industry median: 7.3% (n=302)

View history

NetIncomeLoss YoY

19%

YoY:

Industry median: -0.93% (n=641)

View history

Profitability

Metric Latest value YoY change
Return On Equity 37% -43%
Return On Assets -36% +10%
Operating Margin -39% -64%

Financial Health

Metric Latest value YoY change
Current Ratio 1.57x -26%
Quick Ratio 1.28x -37%
Debt-to-equity -1.92x -30%

Growth

Metric Latest value YoY change
Revenues YoY 91%
NetIncomeLoss YoY 19%

Share Metrics

Metric Latest value YoY change
Entity Common Stock, Shares Outstanding 97,235,316 +3.5%
Common Stock, Shares, Outstanding 97,028,258 +3.6%
Common Stock, Value, Issued $2,000 0%
Weighted Average Number of Shares Outstanding, Basic 96,859,108 +3.6%
Weighted Average Number of Shares Outstanding, Diluted 96,859,108 +3.6%

Additional Metrics

Metric Latest value YoY change
Research and Development Expense $106,841,000 +2.3%
Operating Income (Loss) $146,905,000 +31%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $162,298,000 +28%
Income Tax Expense (Benefit) $21,472,000 +968%
Earnings Per Share, Basic -2 +22%
Earnings Per Share, Diluted -2 +22%
Cash and Cash Equivalents, at Carrying Value $250,590,000 -45%
Marketable Securities, Current $23,847,000 -66%
Cash, Cash Equivalents, and Short-term Investments $274,400,000 -48%
Accounts Receivable, after Allowance for Credit Loss, Current $41,021,000 +117%
Inventory, Net $30,084,000 +347%
Assets, Current $386,586,000 -33%
Property, Plant and Equipment, Net $2,546,000 -14%
Operating Lease, Right-of-Use Asset $7,098,000 -16%
Other Assets, Noncurrent $7,291,000 -60%
Assets $403,521,000 -33%
Accounts Payable, Current $12,217,000 +0.72%
Employee-related Liabilities, Current $23,516,000 +5.9%
Liabilities, Current $245,753,000 -8.7%
Operating Lease, Liability, Noncurrent $5,480,000 -28%
Other Liabilities, Noncurrent $1,717,000 +363%
Liabilities $961,664,000 -7.2%
Retained Earnings (Accumulated Deficit) $1,376,614,000 -15%
Stockholders' Equity Attributable to Parent $558,143,000 -29%
Liabilities and Equity $403,521,000 -33%
Common Stock, Shares Authorized 564,111,242 0%
Common Stock, Shares, Issued 97,028,258 +3.6%
Common Stock, Par or Stated Value Per Share 0 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $256,758,000 -45%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $183,770,000 +19%
Operating Lease, Liability, Current $2,703,000 +32%
Additional Paid in Capital $835,754,000 +7.4%
Share-based Payment Arrangement, Expense $41,463,000 -33%
Interest Expense $18,624,000 +33%

How we score

This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.

Metric Weight V1 threshold
ROIC205% to 20%
ROE158% to 25%
ROA102% to 10%
Operating Margin55% to 25%
Current Ratio121.0x to 2.0x
Quick Ratio80.8x to 1.5x
Debt to Equity100.3x to 2.0x (lower is better)
Revenue YoY10-10% to +20%
Net Income YoY10-10% to +20%

How Calculated (standard_v1)

Metrics are computed with a market-consensus convention designed for cross-portal comparability.

  • TTM Operating Income / TTM Revenues
  • Current Assets / Current Liabilities (latest instant quarter)
  • (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
  • Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
  • TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
  • TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
  • TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
  • TTM Revenues YoY
  • TTM Net Income YoY